Cystic Fibrosis Care Levels Remain Below Pre-Pandemic Standards, Study Shows

As of 2023, care for cystic fibrosis (CF) patients in the U.S. remains below pre-pandemic levels, according to a report by the Cystic Fibrosis Foundation (CFF). The findings highlight ongoing challenges in accessing specialized treatments and consistent medical care, exacerbated by disruptions during the COVID-19 pandemic.

What Has Caused the Decline in Care?

Healthcare access for CF patients faced significant hurdles during the pandemic, including delayed diagnoses, reduced in-person clinic visits, and supply chain issues for essential medications. A 2023 analysis published in the *Journal of Cystic Fibrosis* found that 34% of patients experienced at least one disruption in treatment between 2020 and 2022, compared to 12% in 2019.

“The pandemic created a ripple effect on chronic disease management,” said Dr. Sarah Collins, a pulmonologist at the University of Michigan Health System. “Many patients relied on regular therapies like airway clearance techniques and enzyme replacements, which were harder to access during lockdowns.”

How Are Patients Affected?

Reduced care has led to worsened lung function and increased hospitalizations among CF patients. Data from the CFF’s 2023 Patient Registry shows a 15% rise in emergency department visits for respiratory complications compared to 2019. Patients in rural areas and those with lower socioeconomic status were disproportionately impacted, according to the report.

“Without consistent care, the progressive nature of CF accelerates,” explained Dr. Michael Torres, a CF specialist at Boston Children’s Hospital. “Even small gaps in treatment can lead to long-term damage.”

What Is Being Done to Address the Gap?

Several initiatives aim to restore care levels. The CFF has expanded telehealth services and partnered with pharmacies to ensure medication availability. Additionally, the U.S. Food and Drug Administration (FDA) approved two new CF therapies in 2023, offering hope for improved outcomes.

“We’re seeing progress, but there’s still a long way to go,” said CFF CEO Sue Herrick. “Our focus is on closing the care gap and ensuring every patient receives equitable, timely treatment.”

Why It Matters

The decline in CF care mirrors broader trends in chronic disease management during the pandemic. A 2022 study in *The Lancet* found that 20% of patients with chronic conditions experienced delayed care, leading to preventable complications. For CF, which requires lifelong, multidisciplinary care, these delays pose unique risks.

Experts warn that without sustained investment in CF services, long-term health disparities could widen. “This isn’t just about treating symptoms—it’s about preventing irreversible damage,” said Dr. Collins.

What’s Next for CF Patients?

Advocacy groups are pushing for policy changes to prioritize CF care in public health planning. The CFF is also launching a national campaign to raise awareness about the importance of consistent treatment.

“Patients need to be proactive about their care,” advised Dr. Torres. “Regular check-ups, adherence to treatment plans, and open communication with providers are critical.”